The incidence and associated risk factors for sudden unexplained death in psychiatric in-patients in England and Wales

Abstract

Clinical characteristics and risk factors associated with sudden unexplained death (SUD) in the psychiatric population are unclear. Psychiatric in-patients (England, Wales) who met criteria for SUD were identified (1 March 1999–31 December 2005). Cases were matched with controls (in-patients alive on the day a SUD occurred). Data were collected via questionnaires. Some 283 cases of SUD were identified (41 annually), with a rate of 2.33/10,000 mental health admissions (in England). Electrocardiograms were not routine, cardiopulmonary resuscitation equipment was sometimes unavailable, attempts to resuscitate patients were carried out on one-half of all patients and post mortems/inquiries were not routine. Restraint and seclusion were uncommon. Risk factors included: benzodiazepines (odds ratio (OR): 1.83); ≥2 antipsychotics (OR: 2.35); promazine (OR: 4.02); diazepam (OR: 1.71); clozapine (OR: 2.10); cardiovascular disease (OR: 2.00); respiratory disease (OR: 1.98); diagnosis of dementia (OR: 2.08). Venlafaxine and a diagnosis of affective disorder were associated with reduced ORs (OR: 0.42; OR: 0.65). SUD is relatively rare, although it is more common in older patients and males. Prevention measures may include safer prescribing of antipsychotics and improved physical health care. The contribution of restraint or seclusion to SUD in individual cases is unclear. A uniform definition of SUD may help to identify contributing factors.

Keywords

Drug treatment psychiatric in-patients sudden death

Get full access to this article

View all access options for this article.

References

Anderson

Hill

Broudy

(1994) A population-based autopsy study of sudden, unexpected deaths from natural causes among persons 5 to 39 years old during a 12-year period. Hum Pathol 25: 1332–1339.

Appleby L, Shaw J, Kapur N, Windfuhr K, Ashton A, Swinson N, et al. (2006) Avoidable deaths: five-year report of the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. Available at: http://www.medicine.manchester.ac.uk/nci.

Atkins

Burgess

Bottomley

(1997) Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull R Coll Psychiatr 21: 224–226.

Banerjee

Bingley

Murphy

(1995) Deaths of detained patients. A review of report to the Mental Health Act Commission. UK: Mental Health Foundation.

Bowker

Wood

Davies

Sheppard

Cary

NRB

Burton

JDK

(2003) Sudden unexpected cardiac or unexplained death in England: a national survey. Q J Med 96: 269–279.

British National Formulary (2007) London: British Medical Association and the Royal Pharmaceutical Society of Great Britain.

Cormac

Martin

Ferriter

(2004) Improving the physical health of long-stay psychiatric in-patients. Adv Psychiatr Treat 10: 107–115.

Coulter

Bate

Meyboom

RHB

Lindquist

Edwards

(2001) Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: a data mining study. Br Med J 322: 1207–1207.

Dupont

(2002) Statistical modelling for biomedical researchers. Cambridge: Cambridge University Press, UK.

10.

Glassman

(2005) Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 66 (suppl 6): 5–10.

11.

Glassman

Bigger

Jr (2001) Anti-psychotic drugs: prolonged QT interval, torsade de pointes, and sudden death. Am J Psychiatry 158: 1774–1782.

12.

Hägg

Spigset

Bate

Söderström

(2001) Myocarditis related to clozapine treatment. J Clin Psychopharmacol 21: 382–388.

13.

Hennessy

Bilker

Knauss

Margolis

Kimmel

Reynolds

(2002) Cardiac arrest and ventricular arrhythmia in patients taking anti-psychotic drugs: cohort study using administrative data. Br Med J 325: 1070–1074.

14.

Howell

Wilson

Waring

(2007) Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 64: 192–197.

15.

Isbister

(2009) Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol 67: 572–576.

16.

Kang

Kwon

Ahn

(2000) Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 61: 441–446.

17.

Killian

Kerr

Lawrence

(1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354: 1841–1845.

18.

Mehtonen

Aranko

Malkonen

Vapaatalo

(1991) Survey of sudden death associated with the use of anti-psychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 84: 58–64.

19.

Morentin

Suarez-Mier

Aguilera

(2003) Sudden unexplained death among person 1-25 years old. Forensic Sci Int 135: 213–217.

20.

National Institute for Clinical Excellence (2004) Depression: Management of depression in primary and secondary care. Clinical guideline 23. UK: National Collaborating Centre for Mental Health.

21.

Ray

Chung

Murray

Hall

Stein

(2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Eng J Med 360: 225–235.

22.

Ray

Meredith

Thapa

Meador

Hall

Murray

(2001) Anti-psychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 58: 1161–1167.

23.

Reilly

Ayis

Ferrier

Jones

Thomas

SHL

(2002) Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 180: 515–522.

24.

Royal College of Psychiatrists (1997) The Association Between Anti-psychotic Drugs and Sudden Death. Report of the Working Group of the Royal College of Psychiatrists’ Psychopharamcology Sub-Group, Council Report CR57. London: Royal College of Psychiatrists.

25.

Ruschena

Mullen

Burgess

Cordner

Barry-Walsh

Drummer

(1998) Sudden death in psychiatric patients. Br J Psychiatry 172: 331–336.

26.

Shen

Edwards

Hammill

Bailey

Ballard

Gersh

(1995) Sudden unexpected nontraumatic death in 54 young adults: a 30-year population-based study. Am J Cardiol 76: 148–152.

27.

Stata Corporation (2003) Intercooled STATA 10.0 for Windows. College Station, Texas: Stata Corporation [Statistical Software].

28.

Straus

SMJM

Bleumink

Dieleman

van der Lei

‘t Jong

Kingma

(2004) Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 164: 1293–1297.

29.

Titier

Girodet

P-O

Verdoux

Molimard

Begaud

Haverkamp

(2005) Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf 28: 35–51.

30.

Tungsanga

Sriboonlue

(1993) Sudden unexplained death syndrome in North-East Thailand. Int J Epidemiol 22: 81–87.

31.

Wannamethee

Shaper

Macfarlane

Walker

(1995) Risk factors for sudden cardiac death in middle-aged British men. Circulation 91: 1749–1756.

32.

Wetterling

(2001) Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 24: 59–73.

33.

World Health Organization (1993)The ICD-10 Classification of Mental and Behavioural Disorders: diagnostic criteria for research. Geneva, Switzerland: World Health Organization.

34.

Woods

(2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663–667.

35.

Yorston

Pinney

(2000) Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatr Bull 24: 130–132.